UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

HIV infection: epidemiology, pathogenesis, treatment, and prevention

The Lancet (British edition), 2014-07, Vol.384 (9939), p.258-271

2014

Volltextzugriff (PDF)

The end of AIDS: HIV infection as a chronic disease

The Lancet (British edition), 2013-11, Vol.382 (9903), p.1525-1533

2013

Volltextzugriff (PDF)

Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19

Nature medicine, 2020-04, Vol.26 (4), p.453-455

2020

Volltextzugriff (PDF)

CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART

PLoS pathogens, 2016-07, Vol.12 (7), p.e1005761-e1005761

2016

Volltextzugriff (PDF)

Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society—Lancet Commission

The Lancet (British edition), 2018-07, Vol.392 (10144), p.312-358

2018

Volltextzugriff (PDF)

PD-1 blockade potentiates HIV latency reversal ex vivo in CD4 + T cells from ART-suppressed individuals

Nature communications, 2019-02, Vol.10 (1), p.814-814, Article 814

2019

Volltextzugriff (PDF)

HIV cure and eradication: how will we get from the laboratory to effective clinical trials?

AIDS (London), 2011-04, Vol.25 (7), p.885-897

2011

Volltextzugriff (PDF)

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial

The lancet HIV, 2014-10, Vol.1 (1), p.e13-e21

2014

Volltextzugriff (PDF)

Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection

The Journal of infectious diseases, 2011-03, Vol.203 (6), p.780-790

2011

Volltextzugriff (PDF)

An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients

PLoS pathogens, 2013-12, Vol.9 (12), p.e1003834-e1003834

2013

Volltextzugriff (PDF)

Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells

PLoS pathogens, 2015-10, Vol.11 (10), p.e1005237

2015

Volltextzugriff (PDF)

Perceptions of HIV cure research among people living with HIV in Australia

PloS one, 2018-08, Vol.13 (8), p.e0202647-e0202647

2018

Volltextzugriff (PDF)

Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance

Nature communications, 2021-07, Vol.12 (1), p.1-16, Article 4270

2021

Volltextzugriff (PDF)

The significance and expectations of HIV cure research among people living with HIV in Australia

PloS one, 2020-03, Vol.15 (3), p.e0229733-e0229733

2020

Volltextzugriff (PDF)

Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study

The lancet HIV, 2015-12, Vol.2 (12), p.e520-e529

2015

Volltextzugriff (PDF)

Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy

Nature communications, 2017-07, Vol.8 (1), p.69-69, Article 69

2017

Volltextzugriff (PDF)

Combination Immune Checkpoint Blockade to Reverse HIV Latency

The Journal of immunology (1950), 2020-03, Vol.204 (5), p.1242-1254

2020

Volltextzugriff (PDF)

HDAC inhibitors in HIV

Immunology and cell biology, 2012-01, Vol.90 (1), p.47-54

2012

Volltextzugriff (PDF)

Immune checkpoint blockade in infectious diseases

Nature reviews. Immunology, 2018-02, Vol.18 (2), p.91-104

2018

Volltextzugriff (PDF)

Differential expression of CD163 on monocyte subsets in healthy and HIV-1 infected individuals

PloS one, 2011-05, Vol.6 (5), p.e19968-e19968

2011

Volltextzugriff (PDF)

Soluble immune checkpoints as correlates for HIV persistence and T cell function in people with HIV on antiretroviral therapy

Frontiers in immunology, 2023-03, Vol.14, p.1123342-1123342

2023

Volltextzugriff (PDF)

HIV and co-infections

Immunological reviews, 2013-07, Vol.254 (1), p.114-142

2013

Volltextzugriff (PDF)

Impact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damage

Current opinion in HIV & AIDS, 2015-01, Vol.10 (1), p.35-42

2015

Volltextzugriff (PDF)

HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission

PLoS pathogens, 2015-07, Vol.11 (7), p.e1005000

2015

Volltextzugriff (PDF)

Diverse effects of interferon alpha on the establishment and reversal of HIV latency

PLoS pathogens, 2020-02, Vol.16 (2), p.e1008151-e1008151

2020

Volltextzugriff (PDF)

1 – 25 von 465

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(433)
Mit Volltextzugriff
(402)

Publikationsform

Artikel
(451)
Buchkapitel
(10)
Berichte
(3)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

HIV infection: epidemiology, pathogenesis, treatment, and prevention

The end of AIDS: HIV infection as a chronic disease

Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19

CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART

Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society—Lancet Commission

PD-1 blockade potentiates HIV latency reversal ex vivo in CD4 + T cells from ART-suppressed individuals

HIV cure and eradication: how will we get from the laboratory to effective clinical trials?

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial

Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection

An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients

Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells

Perceptions of HIV cure research among people living with HIV in Australia

Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance

The significance and expectations of HIV cure research among people living with HIV in Australia

Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study

Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy

Combination Immune Checkpoint Blockade to Reverse HIV Latency

HDAC inhibitors in HIV

Immune checkpoint blockade in infectious diseases

Differential expression of CD163 on monocyte subsets in healthy and HIV-1 infected individuals

Soluble immune checkpoints as correlates for HIV persistence and T cell function in people with HIV on antiretroviral therapy

HIV and co-infections

Impact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damage

HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission

Diverse effects of interferon alpha on the establishment and reversal of HIV latency

Suchergebnisse filtern